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Interleukin 1β (IL-1β) is emerging as a master mediator of adult onset Still’s disease (AOSD) pathogenesis. This pleiotropic
cytokine, whose expression is under the control of the inﬂammasome pathway, has a wide type of eﬀects. As a key mediator
of innate immunity is a potent pyrogen and facilitates neutrophilic proliferation and diapedesis into the inﬂamed tissues, which
are key AOSD manifestations. The study of proinﬂammatory cytokines proﬁles in sera and pathological tissues of AOSD patients
has shown elevated levels of IL-1β, these levels being highly correlated with disease activity and severity. These experimental
evidences and the analogy with other autoinﬂammatory diseases that share with AOSD clinical and biological characteristics have
suggested the blockade of IL-1β as a possible new therapeutic option for the AOSD, especially in conventional therapy resistant
cases. Anakinra, the ﬁrst anti-IL-1 agent put on the market, has demonstrated capable to induce a rapid response sustained over
time, especially in systemic forms, where anti-TNFα failed to control symptoms. While a growing number of evidences supports
the utilisation of anakinra in AOSD, a new generation of anti-IL1β antagonists is developing. Canakinumab and rilonacept, thanks
to their higher aﬃnity and longer half-life, could improve the management of this invalidating disease.
1.Introduction
Adult-onset Still’s disease (AOSD) is a systemic autoinﬂam-
matory disorder characterized by daily high-spiking fevers,
evanescent maculopapular rash, sore throat, polyarthritis,
myalgia, lymphadenopathy, and hepatosplenomegaly [1, 2].
The etiology of AOSD is currently unknown. However, a
growing number of experimental evidences supports the hy-
pothesis that a disregulation of inﬂammasome complex and
a related overproduction of the proinﬂammatory cytoki-
ne interleukin 1β (IL-1β) is a pivotal event in the patho-
genesis of this disorder, in analogy with other autoinﬂam-
matory diseases that share with AOSD clinical and biological
characteristics [3].
In this paper, we discuss the biology and the role of IL-1
in AOSD pathogenesis and we review the current literature
about the utilization of anti-IL-1 agents in clinical practice.
2.IL-1Biology
2.1. IL-1 Expression: The Inﬂammasome Pathway of Activa-
tion. IL-1β is a pleiotropic mediator of the response to infec-
tionandinjury,whichaﬀectsnearlyallcelltypes,eitheralone
or in combination with other cytokines. The main source of
IL-1β is the monocytic-macrophagic system.
The components of the latter do not express constitu-
tively this protein whose availability is over the control of the
innateimmunitywhichactsasasophisticatedsystemfordet-
ecting signals of “danger” such as pathogenetic microbes
or host-derived signals of cellular stress. Recognition occurs
through a limited group of pathogen-recognition receptors
(PRRs) like the Toll-like receptors (TLRs) and the NOD-like
receptors (NLRs). It is the crosstalk between TLRs and NLRs
that generate IL1β [4]. For instance, the interaction of TLR
with its ligand triggers pro-IL1β gene expression and synthe-
sis. The conversion of pro-IL1β into active IL1β is mediated2 International Journal of Inﬂammation
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Figure 1: The inﬂammasome pathway of IL-1β activation.
by caspase 1 which requires NLR activation and subsequ-
ent inﬂammasome complex organization to exert its action.
Once secreted, IL-1β binds and activates the single trans-
membrane domain type I IL-1 receptor (IL-1RI) on a variety
of cell types. The following step is the recruitment of IL-1
receptor accessory protein (IL-1RAP) to the IL-1RI/IL-1β
complex. The signal pathway initiated leads ultimately to
nuclear factor κB( N F κB) translocation in the nucleus and
ﬁnally to the expression of an array of inﬂammatory genes
[5–7]( Figure 1).
2.2. An Alternative Pathway of Activation. Interestingly,
recent advances suggest that caspase-1 may not be the only
responsible of IL-1β activation. Neutrophil serine proteases,
mast cell chymase, and metalloproteinases may also be able
toproteolyticallycleavingpro-IL-1β [8,9].Thismayaccount
for the articular damage occurring in AOSD.
2.3. IL-1 Eﬀects
2.3.1. Cytokine Production and Development of Autoinﬂam-
mation. IL-1β upregulates cytokines, acute phase proteins,
and tissue remodeling enzymes. As a key mediator of innate
immunity is a potent pyrogen and facilitates neutrophilic
proliferation and diapedesis into inﬂamed tissues, which are
keyAOSDmanifestations.Intheperiphery,IL-1β,insynergy
with TNF, is recognised as an important factor in driving
bone and cartilage erosion. Of more, it increases platelet
production, which results in thrombocytosis, and promotes
theproductionofIL-6,whichinturnsstimulateshepatocytes
to synthesize several acute phase proteins [10, 11]( Figure 2).
2.3.2. Orientation of the Immune Response. IL-1β also plays
an important role in the adaptive immune response acting
directlyonna¨ ıveandmemoryTcellstopromotetheirexpan-
sion and survival and instructing B cells to enhance anti-
body production. Moreover, it has recently been discover-
ed that IL-1 drives the development of TH17 cells, which are
nowknowntobeakeyT-cellsubsetmediatingmanyautoim-
mune and chronic inﬂammatory diseases. The frequency of
circulating Th17 cells is elevated and positively correlated
with disease activity in AOSD patients [12–16].
2.4. IL-1 Regulation. As it plays a critical role in host defence
eliciting a wide range of eﬀects, the activity of IL-1β needs to
be tighltly controlled to avoid tissue damage resulting in au-
toreactiveresponse.Theregulationtakesplaceonseverallev-
els,includingtranscription,mRNAstability,translation,ma-
turation, secretion, receptor expression, and release of solu-
b l er e c e p t o r s ,a sw e lla sI L - 1 R I I ,ad e c o yr e c e p t o ra n dI L - 1 R a ,
a naturally expressed inhibitor of IL-1 receptor occupancy
[17, 18]. The complexity of IL-1β biology explains well why
the aberrant activation of the innate immunity system can
lead to a multitude of chronic diseases, like AOSD (Figure 1).
3.IL-1β inAOSD Pathogenesis
AOSD is a member of the expanding group of the “autoinﬂa-
mmatory disorders” [19].
In contrast with autoimmunitary diseases that are pri-
marily caused by dysregulation of adaptive immune res-
ponses,autoinﬂammatorydiseasesarecausedbydisordersin
theinnateinﬂammatorypathwaysandtheusualhallmarksof
autoimmunity such as high titers of antigen-speciﬁc T lym-
phocytes and autoantibodies are characteristically absent
[20].
One of the major events in the pathogenesis in these
syndromes is an increased release of active IL-1β. Cytokine
proﬁle in AOSD sera is characterized by the presence of IL-6,
IFNγ, IL-18, and, of note, IL-1β [21, 22].
The identiﬁcation of the critical role of NLRP3 inﬂam-
masome in the maturation of IL-1β motivated the study of
its role in the pathogenesis of autoinﬂammatory syndromes.
Mutations of the inﬂammasome related genes have been
identiﬁed in the cryopyrin-associated periodic syndromes
(CAPSs), in familial Mediterranean fever (FMF) and inInternational Journal of Inﬂammation 3
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Figure 2: IL-1β actions.
the pyogenic arthritis, pyoderma gangrenosum, and acne
syndrome (PAPA). Conversely, in AOSD the cause of innate
immunity disarray still remains unknown.
The primum movens of the pathogenetic sequence seems
to be an infectious agent, as suggested by the temporal rela-
tionship between disease onset and viral syndromes. Other
pathogenic organisms (bacteria, parasites, or chemical eve-
nts) may also be involved. This hypothesis is consistent with
a role of the innate immunity in AOSD. Anyway, infection
alone is unlike to be suﬃcient to trigger AOSD, and a pre-
disposing genetic background is probably required even if
no consistent associations with HLA aplotypes have been
individuated[23].Youmetal.havestudied83AOSDpatients
to investigate whether IL-1β and IL-1Ra gene polymorphi-
smsareassociatedwiththedevelopmentandclinicalfeatures
of AOSD, but no diﬀerences were observed between patients
and healthy controls [24]. A potent IL-1β production-
inducer is IL-18, a member of the IL-1 family that growing
evidences are demonstrating to be pivotal in promoting the
systemic inﬂammatory process of AOSD. IL-18 is impor-
tant in both innate and acquired immune responses. It exerts
pleiotropic eﬀects such as the stimulation of neutrophil
migration and activation, the polarization of T-cell response
versus the Th1 phenotype, the expression of adhesion
molecules and the activation of natural killer cells [25].
It synergizes with IL-6 in the production of ferritin from
macrophage-lineage cells [26] and with IL-23 in the induc-
tion of Th17 cells [16]. IL-18 serum levels are higher in
AOSD patients compared to other autoinﬂammatory disea-
ses [27] and correlate with disease activity, serum ferritin
levels, and neutrophil count. The local expression of IL-18
may be responsible for tissue damage in some target organs
such liver [28] and synovial membranes [29].
However, actually the most convincing case supporting
the central role of IL-1β in AOSD pathogenesis is the
dramatic and sustained eﬃcacy of IL1-blockade on AOSD
symptoms, even in refractory forms of the disease.
4. IL-1-Targeting Therapies
4.1. Anakinra. Anakinra (Kineret) is the ﬁrst IL-1 inhibitor
designed. It is a recombinant, nonglycosylated form of hu-
man IL-1 receptor that acts as a pure receptor antagonist
binding tightly to the IL-1RI and preventing activation of
this receptor by either IL-1β or IL-1α. It is administered
subcutaneously once daily, due to its short half-life. Approv-
ed by the FDA in 2001 for treating patients with rheumatoid
arthritis, its use validated the importance of IL-1 in a
broadspectrumofinﬂammatorydiseases,AOSDincluded.A
growing number of reports describe a rapid response to ana-
kinra characterized by impressive reduction in disease activ-
ity, fever resolution, and normalization of hematologic and
biochemical parameters within hours to days after the ﬁrst
injection in patients aﬀected from AOSD refractory to other
synthetic or biological treatment [3, 22, 30–34]. These eﬀects
are likely to be sustained over a long treatment period and
allow tapering and withdrawal of concomitant glucocor-
ticoids and DMARDs and ﬁnally anakinra administration
in monotherapy [34–36]. Such a long-lasting eﬀect was
not described with TNF-blockers, whose eﬃcacy seems to
decreaseovertime[37].Ourgrouphasobservedthatinsome
patients that achieved a complete and stable remission was
possiblenotonlyadiscontinuationorreductionoftreatment
associated, but also of anakinra itself, without relapse [38].
T h e s ed a t as e e mt ob ec o n ﬁ r m e db yt h er e t r o s p e c t i v es t u d y
of Laskari et al. [36]. The possibility of dose reduction may
enhance compliance and drug adherence and highlights the
potential cost-eﬀectiveness of anakinra. Moreover, accord-
ing to our observations, the most impressive results were
obtained in patients with systemic forms. This is consistent4 International Journal of Inﬂammation
Table 1: Anti-IL1 agents.
Biologic agent target
cytokine(s) Molecular characteristics Doses (route of administration) Recorded indications
Anakinra (Kineret) IL-1α
and IL-1β
Recombinant human IL-1
receptor antagonist 100mg/day (sc) Rheumatoid arthritis
Rilonacept (Regeneron)
IL-1α and IL-1β
Fusion protein of the
extracellular domains of
IL-1R1 and IL-1RAP,
coupled to the Fc region
of human IgG
Induction dose: 320mg
maintenance: 160mg/week (sc)
Cryopyrin-associated periodic
syndromes (CAPSs)
Canakinumab (Ilaris) IL-1β Fully human monoclonal
anti-IL1β antibody 150mg every 8 weeks (sc) Cryopirin-associated periodic
syndromes (CAPSs)
Gevokizumab (Xoma 052)
IL-1β
Recombinant humanized
anti-IL1β antibody
Not labeled potential
therapeutic use: Behc ¸et’s
uveitis, types 1 and 2 diabetes,
and rheumatoid arthritis (phase
II trials)
sc: subcutaneous.
with data reported by Lequerr´ e et al. [34]. We can argue that
the proinﬂammatory cytokine IL-1 could have a more pro-
minent role in systemic forms of AOSD for whom Anakinra
use can be reserved. In these cases, Anakinra may be
eﬃcacious not only to induce remission, but also to prevent
new relapses in polycyclic forms and the amyloidosis devel-
opment associated with long-standing elevated inﬂamma-
tory markers. Methotrexate and TNF-blockers may remain
interesting in chronic articular presentation of AOSD [39].
Another open question is whether anakinra must be
introduced early in the course of AOSD or only after other
conventional treatment failure to avoid the adverse eﬀects
of a prolonged corticotherapy and to limit the social impact
of a poorly controlled disease [2]. To support the necessity
of an earlier introduction of anakinra, Moulis et al. have
reported two cases of dramatic side eﬀects secondary to
conventional treatment that later had an immediate and
remarkable response after anakinra starting [40].
Immunomodulation by anti-IL1 is rather safe and well
tolerated. The most frequent adverse event reported in the
clinical trials is injection-site reaction which is generally
mild to moderate and rapidly resolutive. Some infections
have been reported; however, it has not been associated with
the development of tuberculosis or other fungal infections,
demyelinating syndromes or worsening of congestive heart
failure [41]. A recent systematic review of literature conduct-
ed by Singh et al. on 163 randomized controlled trials with
50,010 participants and 46 extension studies with 11,954
participants that included indirect comparisons between
anakinra and other biological agents revealed that anakinra
is associated with a signiﬁcantly lower risk of serious adverse
events compared to most other biologic treatments [42].
Anecdotally, we report a severe systemic inﬂammatory res-
ponsesyndromeafteranakinraintroduction[43]andanepi-
sode of thrombocytopenia, which appeared one week after
anakinra introduction and resolved soon after its discontin-
uation [44].
Immunization against anakinra has been described,
but the appearance of potentially neutralizing antibodies
is transient and has never been associated with anakinra
failure subsequently do not preventing chronical anakinra
administration [45].
In conclusion, even if more studies are needed, all the
evidences actually available strongly support the importance
of anakinra as new safe and eﬀective therapeutic option in
AOSD treatment.
4.2. Next Generation Anti-IL-1β Antagonists. Although ana-
kinra hasbeendemonstratedeﬀectiveandsafe,itsshorthalf-
life demanding daily injections often associated with painful
local adverse reactions limits its usefulness in the clinical
practice. This has represented an incentive to the develop-
ment of new anti-IL1β antagonists with diﬀerent pharma-
cokinetic properties. Recently, soluble receptors for IL-1
(rilonacept) and human mAbs to IL-1β (canakinumab and
gevokizumab) have been used to neutralize IL-1β speciﬁcally
(Table 1).
Rilonacept (Regeneron) is a construct of 2 extracellular
chains of the IL-1R complex (IL-1R plus IL-1RAP) fused
to the Fc portion of human IgG1. Since it contains both
receptor components, rilonacept is able to bind IL-1β
and IL-1α with high aﬃnity. It has an half-life is longer
that anakinra, and it is administrated once weekly [46].
Henderson et al. investigated the use of rilonacept in a
small cohort of refractory AOSD patients observing a good
clinical and biological response. Interestingly, they reported
that high levels of IL-18 at baseline were predictors of a
successful response. This evidence suggests this biomarker as
a useful tool to predict response to treatment [47].
Canakinumab (Ilaris) is a human monoclonal IgG1
antibody targeted against IL-1β, thus preventing its binding
to the receptor complex. Generated by a transgenic mouse
strain, it oﬀers a high speciﬁcity for IL-1β.A m o n gI L - 1
antagonists, canakinumab is the agent with the longest half-
life. Of more, it has been demonstrated that its clinical eﬃca-
c yi sp r o l o n g e db e y o n dw h a te x p e c t e db a s e do ni t sh a l f -
life. Subsequently, pharmacokinetic modelings have shown a
positive feedback of IL-1β on its own production. This ex-
plains why the eﬀectiveness of the drug is greater than its
half-life, thus permitting its administration once every twoInternational Journal of Inﬂammation 5
months [48, 49]. In clinical trials, canakinumab and rilona-
ceptareassociatedwithamildincreaseofinfections.Therate
of injection site injections was 34% versus 27% in rilonacept
versus placebo and 9% versus 14% in canakinumab versus
placebo [50, 51].
Actually, canakinumab and rilonacept are indicated only
forthetreatmentoftheCAPS,buttheycouldrepresentanew
therapeutic option for AOSD [52, 53].
Gevokizumab (XOMA 052) is an IgG2-humanized mAb
against human IL-1β. XOMA has completed a successful
proof-of-concept Phase 2 trial of gevokizumab in patients
with Behc ¸et’s uveitis, types 1 and 2 diabetes, and rheumatoid
arthritis. It belongs the potential to treat patients with a wide
variety of inﬂammatory diseases, including autoinﬂamma-
tory diseases [54, 55].
The development of IL-1β blockers with higher aﬃnity
and longer half-life could improve patient management and
also favor patient compliance.
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